48Roberts JM, Gurley M, Thurloe JK, Bowditch R, Laverty CRA. Evaluation of the ThinPrep Pap test as an adjunct to theconventional Pap smear. Med J Aust 1997; 167:466-469.49Armstrong GP, Moriaty HT, Krajewska I. An in-house evaluation of the ThinPrep split-sample Pap test. Am J Med Sci 2002;23:162-173.50Kirschner B, Junge J, Simonsen K. Sammenligning af konventionel smear<strong>teknik</strong> a.m. Papanicolaou <strong>og</strong> væskebaseret cytol<strong>og</strong>ived <strong>screening</strong> <strong>for</strong> livmoderhalskræft i Københavns <strong>og</strong> Frederiksberg Kommuner (H:S) 2000-2004. 2004 Poster ved årsmødeDansk Selskab <strong>for</strong> Patol<strong>og</strong>isk anatomi <strong>og</strong> cytol<strong>og</strong>i.51Limaye A, Connor AJ, Huang X, Luff R. Comparative analysis of conventional Papanicolaou tests and a fluid-based thinlayermethod. Arch Pathol Lab Med 2003; 127:200-204.52McGo<strong>og</strong>an E, Reith A. Would monolayers provide more representative samples and improved preparations <strong>for</strong> cervical<strong>screening</strong>? Overview and evaluation of systems available. Acta Cytol 1996; 40:107-119.53Vassilakos P, Cossali D, Albe X, Alonso L, Hohener R, Puget E. Efficacy of monolayer preparations <strong>for</strong> cervical cytol<strong>og</strong>y.Emphasis on sub-optimal specimens. Acta Cytol 1996; 40:496-500.54Lee KR, Ashfaq R, Birdsong GG, Corkill ME, Mcintosh KM, Inhorn SL. Comparison of conventional Papanicolaou smearsand a fluid-based, thin-layer system <strong>for</strong> cervical cancer <strong>screening</strong>. Obstet Gynecol 1997; 90:278-284.55Takahashi M, Naito M. Application of the Cytorich monolayer preparation system <strong>for</strong> cervical cytol<strong>og</strong>y. A prelude toautomated primary <strong>screening</strong>. Acta Cytol 1997; 41:1785-1789.56Bolick DR, Hellman DJ. Laboratory implementation and efficacy assessment of the ThinPrep cervical cancer <strong>screening</strong>system. Acta Cytol 1998; 42:209-213.57Corkill M, Knapp D, Hutchinson ML. Improved accuracy <strong>for</strong> the cervical cytol<strong>og</strong>y with ThinPrep method and the endocervicalbrush-spatula collection procedure. J Low Genit Tract Dis 1998; 2:12-216.58Dupree WB, Suprun HZ, Beckwith DG, Shane JJ, Lucente V. The promise and risk of a new technol<strong>og</strong>y. The Lehigh ValleyHospital’s experience with liquid-based cervical cytol<strong>og</strong>y. Cancer (Cytopathol<strong>og</strong>y) 1998; 84:202-207.59Papillo JL, Zarka MA, St John TL. Evaluation of the ThinPrep Pap test in clinical practice. A seven-month, 16.314-caseexperience in Northern Vermont. Acta Cytol 1998; 42:203-208.60Stevens MW, Nespolon WW, Milne AJ, Rowland R. Evaluation of the cytorich technique <strong>for</strong> cervical smears. Diag Cytopathol1998; 18:236-242.61Carpenter AB, Davey DD. The ThinPrep Pap test. Per<strong>for</strong>mance and biopsy follow-up in a university hospital. Cancer(Cancer Cytopathol) 1999; 87:105-112.62Diaz-Rosario LA, Kabawat SE. Per<strong>for</strong>mance of a fluid-based, thin-layer Papanicolaou smear method in the clinical settingof an independent laboratory and an outpatient <strong>screening</strong> population in New England. Arch Pathol Lab Med 1999; 123:817-821.63Guidos BJ, Selvaggi SM. Use of the Thin Prep Pap Test in clinical practice. Diag Cytopathol 1999; 20:70-73.64Hutchinson ML, Zahniser DJ, Sherman ME, Herrero R, Alfaro M, Hildesheim A, Lorincz AT, Greenberg MD, Morales J,Schiffman M. U<strong>til</strong>ity of liquid-based cytol<strong>og</strong>y <strong>for</strong> cervical carcinoma <strong>screening</strong>. Results of a population-based study conductedin a region of Costa Rica with a high incidence of cervical carcinoma. Cancer (Cancer Cytopathol) 1999; 87:48-55.Væskebaseret <strong>teknik</strong> <strong>og</strong> udstrygnings<strong>teknik</strong> <strong>anvendt</strong> <strong>til</strong> <strong>screening</strong> <strong>for</strong> livmoderhalskræft i Danmark 43
65Yeoh GPS, Chan KW, Lauder I, Lam MB. Evaluation of the ThinPrep Papanicolaou test in clinical practice: 6 month studyof 16.541 cases with histol<strong>og</strong>ical correlation in 220 cases. HKMJ 1999; 5:233-239.66Ferris DG, Heidemann NL, Litaker MS, Crosby JH, Macfee MS. The efficacy of liquid-based cervical cytol<strong>og</strong>y using directto-vialsample collection. J Fam Pract 2000; 49:1005-1011.67Minge L, Fleming M, VanGeem T, Bishop JW. AutoCyte prep system vs. Conventional cervical cytol<strong>og</strong>y. Comparison basedon 2.156 cases. J Reprod Med 2000; 45:179-184.68Tench W. Preliminary assessment of the AutoCyte prep. Direct-to-vial per<strong>for</strong>mance. J Reprod Med 2000; 45:912-916.69Vassilakos P, Schwartz DS, de Marval F, Yousfi L, Broquet G, Mathez-Loic F, Campana A, Major A. Biopsy-based comparisonof liquid-based thin-layer preparations to conventional Pap smears. J Reprod Med 2000; 45:11-16.70Weintraub J, Morabia A. Efficacy of a liquid-based thin layer method <strong>for</strong> cervical cancer <strong>screening</strong> in a population witha low incidence of cervical cancer. Diag Cytopathol 2000; 22:52-59.71Hessling JJ, Raso DS, Schiffer B, Callicott J, Husain M, Taylor D. Effictiveness of thin-layer preparations vs. conventionalPap smears in a blinded, split-sample study. J Reprod Med 2001; 46:880-886.72Marino JF, Fremont-Smith M. Direct-to-vial experience with AutoCyte Prep in a small New England regional cytol<strong>og</strong>ypractice. J Reprod Med 2001; 46:353-358.73Monsonego J, Au<strong>til</strong>lo-Touati A, Bergeron C, Dachez R, Liaras J, Saurel J, Zerat L, Chatelain P, Mottot C. Liquid-basedcytol<strong>og</strong>y <strong>for</strong> primary cervical cancer <strong>screening</strong>: a multi-centre study. Br J Cancer 2001; 84:360-366.74Obwegeser JH, Brack S. Does liquid-based technol<strong>og</strong>y really improve detection of cervical neoplasia? A prospective,randomized trial comparing the ThinPrep Pap test with the conventional Pap test, including follow-up of HSIL cases.Acta Cytol 2001; 45:709-714.75Biscotti CV, O’Brian DL, Gero MA, Gramlich TL, Kennedy AW, Easley KA. Thin-layer Pap test vs. conventional Pap smear.Analysis of 400 split samples. J Reprod Med 2002; 47:9-13.76Grace A, McBrearty P, Troost S, Kay E, Leader M. Comparative study: conventional cervical and ThinPrep Pap tests in aroutine clinical setting. Cytopathol<strong>og</strong>y 2002; 13:200-205.77Luthra U, Chishti M, Dey P, Jolly SV, Abdulla A, Das DK, Sugathan TN, Ajrawi MT, George J, George SS, Aziz AA, Al-Juwaiser A, Karim FA, Mallik MK, Sheikh ZA, Khan S. Per<strong>for</strong>mance of monolayer cervical smears in a gynecol<strong>og</strong>y outpatientsetting in Kuwait. Acta Cytol 2002; 46:303-310.78Cheung ANY, Szeto EF, Leung BS, Khoo US, Ng AW. Liquid-based cytol<strong>og</strong>y and conventional cervical smears. A comparisonstudy in an asian <strong>screening</strong> population. Cancer (Cancer Cytopathol) 2003; 99:331-335.79Coste J Cochand-Prillet B, de Cremoux P, Le Galès C, Cartier I, Molinié V, Labbé S, Vacher-Lavenu MC, Viehl P. Crosssectional study of conventional cervical smear, monolayer cytol<strong>og</strong>y, and human papillomavirus DNA testing <strong>for</strong> cervicalcancer <strong>screening</strong>. BMJ 2003; 326:1-5.80Farnsworth A. Liquid-based cytol<strong>og</strong>y: an australian experience. Cytopathol<strong>og</strong>y 2003; 14:48-52.81Harkness CB, Theofrastous JP, Ibrahim SN, Galvin SL, Lawrence HC. Papanicolaou and thin-layer cervical cytol<strong>og</strong>y withcolposcopic biopsy control. J Reprod Med 2003; 48(9):681-686.Væskebaseret <strong>teknik</strong> <strong>og</strong> udstrygnings<strong>teknik</strong> <strong>anvendt</strong> <strong>til</strong> <strong>screening</strong> <strong>for</strong> livmoderhalskræft i Danmark 44
- Page 1 and 2: VÆSKEBASERET TEKNIK OG UDSTRYGNING
- Page 3 and 4: ForordForebyggende undersøgelser m
- Page 5 and 6: 5 Organisation 585.1 Indledning 585
- Page 7 and 8: herunder relateret til automatisere
- Page 9 and 10: SummaryConclusionsMain conclusions:
- Page 11 and 12: equate tests may be reduced. Conver
- Page 13 and 14: OrdlisteASCUS - atypical squamous c
- Page 15 and 16: PrepStain - produktnavn: system, de
- Page 17 and 18: 2003. Her fremkom de amerikanske og
- Page 19 and 20: Til udarbejdelse af rapporten er ne
- Page 21 and 22: 2 Teknologi2.1 Beskrivelse af tekno
- Page 23 and 24: ne i et screeningsprogram mod livmo
- Page 25 and 26: HHKvinder i samme population får p
- Page 27 and 28: hvilke celleprøver, der skal kalde
- Page 29 and 30: Rapporten gennemgik litteraturen fo
- Page 31 and 32: K. Nanda et al. 2000 (USA) (20)UST,
- Page 33 and 34: Konklusion af reviewartiklerI fem u
- Page 35 and 36: M. Fremont-Smith et al. 2004 (USA)
- Page 37 and 38: verificeres, giver en bias til ford
- Page 39 and 40: HHHDer er ikke videnskabeligt belæ
- Page 41: 32Bishop JW, Bigner SH, Colgan TJ,
- Page 45 and 46: 3 Patientperspektivet3.1 Indledning
- Page 47 and 48: 4 Økonomi4.1 IndledningTidligere
- Page 49 and 50: TABEL 4.2Gennemsnitlige omkostninge
- Page 51 and 52: eløb som dækkende, er der en merp
- Page 53 and 54: TABEL 4.6Omkostninger, som er uafh
- Page 55 and 56: implementering af VBT frem for UST,
- Page 57 and 58: 5 Organisation5.1 IndledningI Danma
- Page 59 and 60: Deltagerprocenten varierer fra 49%
- Page 61 and 62: Forhold vedrørende cytobioanalytik
- Page 63 and 64: EgnethedskriterierTABEL 5.6Anvendte
- Page 65 and 66: Undersøgelse af celleprøver fra l
- Page 67 and 68: amter i forhold til at reducere and
- Page 69 and 70: 2Seminar om screening for livmoderh
- Page 71 and 72: Ved beslutning om anvendelse af UST
- Page 73 and 74: 7 BilagBilag 1 - TidsstudieBilag 2
- Page 75 and 76: IndledningBaggrund for projektetDen
- Page 77 and 78: Arbejdsgange og aktiviteterCellemat
- Page 79 and 80: ÅrhusTidsstudiet fandt sted i uge
- Page 81 and 82: er der forskellig praksis med hensy
- Page 83 and 84: BILAG1-TABEL 5Minutter per cellepr
- Page 85 and 86: af præparatet (15). Da UST er mere
- Page 87 and 88: 14Cheung ANY, Szeto EF, Leung BS, K
- Page 89 and 90: Bilag 2 - Supplerende baggrundsmate
- Page 91 and 92: OR test OR tests OR prevention OR c
- Page 93 and 94:
Væskebaseret teknik og udstrygning
- Page 95 and 96:
Væskebaseret teknik og udstrygning
- Page 97 and 98:
Bilag 2.2 Bilag vedr. kapitel 4-Øk
- Page 99 and 100:
Bilag 2.2.3 Incidens af livmoderhal
- Page 101 and 102:
PræscreeningsforløbI det følgend
- Page 103 and 104:
adskille celleprøver uden for invi
- Page 105 and 106:
BILAG 2.3.2 - TABEL 2Diagnosefordel
- Page 107:
Tabellen over årsag til at en cell